HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith-Jones, P. M. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Smith-Jones, P. M. Articles by Larson, S. M.

Early Tumor Response to Hsp90 Therapy Using HER2 PET: Comparison with ¹⁸F-FDG PET

¹ Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and ² Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence or reprints contact: Peter M. Smith-Jones, PhD, Nuclear Medicine Service, Box 77, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. E-mail: smith-jp{at}mskcc.org

We compared ⁶⁸Ga-DOTA-F(ab')₂-herceptin (DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid [HER2 PET]) and ¹⁸F-FDG PET for imaging of tumor response to the heat shock protein 90 (Hsp90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG). Methods: Mice bearing BT474 breast tumor xenografts were scanned with ¹⁸F-FDG PET and HER2 PET before and after 17AAG treatment and then biweekly for up to 3 wk. Results: Within 24 h after treatment, a significant decrease in HER2 was measured by HER2 PET, whereas ¹⁸F-FDG PET uptake, a measure of glycolysis, was unchanged. Marked growth inhibition occurred in treated tumors but became evident only by 11 d after treatment. Thus, Her2 downregulation occurs independently of changes in glycolysis after 17AAG therapy, and Her2 reduction more accurately predicts subsequent tumor growth inhibition. Conclusion: HER2 PET is an earlier predictor of tumor response to 17AAG therapy than ¹⁸F-FDG PET.

This article has been cited by other articles:

				R. M. Reilly Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer Therapy J. Nucl. Med., July 1, 2009; 50(7): 1017 - 1019. [Full Text] [PDF]

				G. Kramer-Marek, D. O. Kiesewetter, and J. Capala Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules J. Nucl. Med., July 1, 2009; 50(7): 1131 - 1139. [Abstract] [Full Text] [PDF]

				E. C.F. Dijkers, J. G.W. Kosterink, A. P. Rademaker, L. R. Perk, G. A.M.S. van Dongen, J. Bart, J. R. de Jong, E. G.E. de Vries, and M. N. Lub-de Hooge Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging J. Nucl. Med., June 1, 2009; 50(6): 974 - 981. [Abstract] [Full Text] [PDF]

				J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions J. Nucl. Med., May 1, 2009; 50(5): 738 - 748. [Abstract] [Full Text] [PDF]

				K. B. Contractor and E. O. Aboagye Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 97S - 105S. [Abstract] [Full Text] [PDF]

				M. P.S. Dunphy and J. S. Lewis Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 106S - 121S. [Abstract] [Full Text] [PDF]

				M. A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer Ann. Onc., February 1, 2009; 20(2): 213 - 226. [Abstract] [Full Text] [PDF]

				B. Zhao, L. H. Schwartz, and S. M. Larson Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers J. Nucl. Med., February 1, 2009; 50(2): 239 - 249. [Abstract] [Full Text] [PDF]

				A. M. Wu Antibodies and Antimatter: The Resurgence of Immuno-PET J. Nucl. Med., January 1, 2009; 50(1): 2 - 5. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, et al. Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer J Natl Cancer Inst, April 18, 2007; 99(8): 628 - 638. [Abstract] [Full Text] [PDF]

				A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandstrom, F. Y. Nilsson, A. Wennborg, L. Abrahmsen, and J. Feldwisch Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors Cancer Res., March 1, 2007; 67(5): 2178 - 2186. [Abstract] [Full Text] [PDF]

				W. A. Weber Chaperoning Drug Development with PET J. Nucl. Med., May 1, 2006; 47(5): 735 - 737. [Full Text] [PDF]